Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products. The Branded Products segment focuses on multisource products accessible without active ingredient research, notably anti-enzymatic food intolerance drugs that are marketed by the subsidiary SCIOTEC Diagnostics Technologies. The Company's generic drugs are marketed by the Group subsidiary, STADApharm GmbH. Non-core activities of the Company encompass Commercial Business segment, which includes activities with primarily trading character such as wholesaling activities. The Company operates STADA Pharmaceuticals Australia Pty Ltd and STADA IT SOLUTIONS DOO as subsidiaries.

Pharmaceutical

Stada Group

Peter Goldschmidt

Christos Gallis

Stéphane Jacqmin

Boris Doebler

Simone Berger

Christoph Dengler

Bryan Kim

Miguel Pagan Fernandez

Stephan Eder

Volker Sydow

Frank Staud

Yann Brun

The current leadership team at Stada Group has a wide range of experience in the pharmaceutical and healthcare industries. Many members have worked for large companies such as Samsung, Boehringer Ingelheim, Pfizer, and Teva Pharmaceuticals. Others have experience in strategic planning, legal counsel, and human resources. The team is well-educated, with degrees from universities such as The Johns Hopkins University, EBS Universität, Johannes-Gutenberg Universität, and Harvard Business School.

Leadership Team

CEO and Executive Team

Board of Directors

Leadership Team

About

Team members

Other teams at Stada Group

CEO and Executive Team

Board of Directors